Minimum Oxytocin Dose for Cesarean During Labor: Adaptative Clinical Trial
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Introduction: postpartum hemorrage is a leading cause of death after cesarean sections in
Brazil. Oxytocin is the main drug for both prophylaxis and threatment of postpartum hemorrage
because uterine atony is the most prevalent cause. Both excessive and too low oxytocin doses
threaten the life of women.
Objective: to determine the minimum effective dose of oxytocin for cesareans during labor.
Method: adaptative clinical trial using a modified up and down method of two sequential
groups: rule of three and continuous infusion. Allocation in rule of three or continuous
infusion will be random and masked for patients and anesthesiologists. The minimum effective
dose will be the effective dose for 90% of success (ED90 for preventing uterine atony).